Amylyx Pharmaceuticals (AMLX)
(Real Time Quote from BATS)
$1.98 USD
-0.01 (-0.50%)
Updated May 7, 2024 10:24 AM ET
4-Sell of 5 4
F Value A Growth A Momentum C VGM
Price, Consensus and EPS Surprise
AMLX 1.98 -0.01(-0.50%)
Will AMLX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AMLX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMLX
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
AMLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%
Other News for AMLX
Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
Commit To Buy Amylyx Pharmaceuticals At $1, Earn 6.7% Annualized Using Options
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Amylyx Pharmaceuticals Inc (AMLX) and Rhythm Pharmaceuticals (RYTM)
Amylyx Pharmaceuticals: A Hold Rating Amidst Promising but Preliminary HELIOS Trial Results
Hold Rating on Amylyx Pharmaceuticals Amid Uncertainties in Drug Efficacy and Market Prospects